Barclays lowered the firm’s price target on MetLife (MET) to $90 from $98 and keeps an Overweight rating on the shares. The firm is “cautiously optimistic” on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. Barclays adjusted ratings and price targets as part of its 2026 outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MET:
- MetLife downgraded to In Line from Outperform at Evercore ISI
- MetLife price target lowered to $98 from $100 at BofA
- MetLife Completes PineBridge Acquisition, Expanding Global Asset Management
- MetLife Updates 2025 Results Outlook and Capital Plans
- Dollar General, BMY, PRU, MET, Snowflake Trending With Analysts